These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8243362)

  • 1. Hematologic manifestations of long-term valproate therapy.
    May RB; Sunder TR
    Epilepsia; 1993; 34(6):1098-101. PubMed ID: 8243362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report on reversible Pelger-Huët anomaly depending on serum free fraction of valproic acid.
    Suzuki K; Hiramoto A; Okumura T
    Brain Dev; 2015 Mar; 37(3):344-6. PubMed ID: 24985021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrocytosis associated with divalproex treatment.
    Tsivkin R; Saito E; Kafantaris V
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):1011-4. PubMed ID: 16379522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy.
    Geda G; Caksen H; Içağasioğlu D
    Acta Neurol Belg; 2002 Sep; 102(3):122-6. PubMed ID: 12400250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction.
    Kurahashi H; Takami A; Murotani K; Numoto S; Okumura A
    Int J Hematol; 2018 Jan; 107(1):105-111. PubMed ID: 28879549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytopenia secondary to high valproate levels in children with epilepsy.
    Delgado MR; Riela AR; Mills J; Browne R; Roach ES
    J Child Neurol; 1994 Jul; 9(3):311-4. PubMed ID: 7930412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy.
    Hauser E; Seidl R; Freilinger M; Male C; Herkner K
    Brain Dev; 1996; 18(2):105-9. PubMed ID: 8733899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate-induced thrombocytopenia: a prospective monotherapy study.
    Nasreddine W; Beydoun A
    Epilepsia; 2008 Mar; 49(3):438-45. PubMed ID: 18031547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic-acid-induced thrombocytopenia and hepatotoxicity: discontinuation of treatment?
    Lackmann GM
    Pharmacology; 2004 Feb; 70(2):57-8. PubMed ID: 14685007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe hematologic toxicity of valproic acid. A report of four patients.
    Ganick DJ; Sunder T; Finley JL
    Am J Pediatr Hematol Oncol; 1990; 12(1):80-5. PubMed ID: 2106802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration.
    Gidal B; Spencer N; Maly M; Pitterle M; Williams E; Collins M; Jones J
    Neurology; 1994 Aug; 44(8):1418-22. PubMed ID: 8058141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sodium valproate, platelet dysfunction and bleeding (author's transl)].
    Loiseau P
    Nouv Presse Med; 1981 Dec; 10(46):3789-90. PubMed ID: 6798554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid and thrombocytopenia in children: a case-controlled retrospective study.
    Allarakhia IN; Garofalo EA; Komarynski MA; Robertson PL
    Pediatr Neurol; 1996 May; 14(4):303-7. PubMed ID: 8805173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe, isolated thrombocytopenia under polytherapy with carbamazepine and valproate.
    Finsterer J; Pelzl G; Hess B
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):423-6. PubMed ID: 11442896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in red blood cells with valproate therapy.
    Ozkara C; Dreifuss FE; Apperson Hansen C
    Acta Neurol Scand; 1993 Sep; 88(3):210-2. PubMed ID: 8256557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital.
    Conley EL; Coley KC; Pollock BG; Dapos SV; Maxwell R; Branch RA
    Pharmacotherapy; 2001 Nov; 21(11):1325-30. PubMed ID: 11714204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy.
    Rosenfeld WE; Liao S; Kramer LD; Anderson G; Palmer M; Levy RH; Nayak RK
    Epilepsia; 1997 Mar; 38(3):324-33. PubMed ID: 9070595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic lupus erythematosus associated with use of valproate.
    Asconapé JJ; Manning KR; Lancman ME
    Epilepsia; 1994; 35(1):162-3. PubMed ID: 8112240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium valproate and platelet counts.
    Eastham RD; Jancar J
    Br Med J; 1980 Jan; 280(6208):186. PubMed ID: 6766772
    [No Abstract]   [Full Text] [Related]  

  • 20. Valproic acid and immune thrombocytopenia.
    Barr RD; Copeland SA; Stockwell ML; Morris N; Kelton JC
    Arch Dis Child; 1982 Sep; 57(9):681-4. PubMed ID: 6812506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.